Načítá se...
Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus
Acute treatment of hereditary angioedema due to C1 inhibitor deficiency has become available in the last 10 years and has greatly improved patients’ quality of life. Two plasma-derived C1 inhibitors (Berinert and Cinryze), a recombinant C1 inhibitor (Ruconest/Conestat alpha), a kallikrein inhibitor...
Uloženo v:
| Vydáno v: | Front Med (Lausanne) |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5857575/ https://ncbi.nlm.nih.gov/pubmed/29594115 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2017.00245 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|